Analysts expect Esperion Therapeutics Inc (NASDAQ:ESPR) to post earnings of ($1.36) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Esperion Therapeutics’ earnings, with the lowest EPS estimate coming in at ($1.63) and the highest estimate coming in at ($1.05). Esperion Therapeutics reported earnings of ($1.44) per share during the same quarter last year, which indicates a positive year over year growth rate of 5.6%. The firm is expected to issue its next quarterly earnings report on Tuesday, February 19th.

According to Zacks, analysts expect that Esperion Therapeutics will report full year earnings of ($6.54) per share for the current financial year, with EPS estimates ranging from ($6.73) to ($6.35). For the next fiscal year, analysts anticipate that the company will report earnings of ($5.55) per share, with EPS estimates ranging from ($7.75) to ($4.02). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that cover Esperion Therapeutics.

Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings data on Thursday, November 1st. The biopharmaceutical company reported ($1.86) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.58) by ($0.28). During the same quarter in the previous year, the business posted ($1.86) EPS.

Several analysts recently commented on ESPR shares. Citigroup upgraded shares of Esperion Therapeutics from a “neutral” rating to a “buy” rating and raised their price objective for the company from $57.00 to $75.00 in a research note on Friday, August 17th. Stifel Nicolaus started coverage on shares of Esperion Therapeutics in a research note on Friday, September 14th. They issued a “buy” rating and a $89.00 price objective for the company. BidaskClub cut shares of Esperion Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, September 22nd. Zacks Investment Research upgraded shares of Esperion Therapeutics from a “hold” rating to a “buy” rating and set a $51.00 price objective for the company in a research note on Wednesday, October 3rd. Finally, BTIG Research started coverage on shares of Esperion Therapeutics in a research note on Tuesday, October 16th. They issued a “buy” rating and a $82.00 price objective for the company. Two research analysts have rated the stock with a sell rating, three have given a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $75.96.

Shares of NASDAQ ESPR opened at $51.49 on Friday. Esperion Therapeutics has a 52 week low of $33.06 and a 52 week high of $82.68. The stock has a market capitalization of $1.45 billion, a P/E ratio of -7.38 and a beta of 2.36.

In other news, Director Roger S. Newton sold 2,827 shares of Esperion Therapeutics stock in a transaction dated Friday, November 2nd. The shares were sold at an average price of $50.07, for a total transaction of $141,547.89. Following the completion of the sale, the director now directly owns 573,953 shares in the company, valued at $28,737,826.71. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder Boxer Capital, Llc sold 100,000 shares of Esperion Therapeutics stock in a transaction dated Monday, November 5th. The stock was sold at an average price of $56.38, for a total transaction of $5,638,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 152,327 shares of company stock valued at $8,463,042 over the last 90 days. 32.50% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently modified their holdings of ESPR. Opera Trading Capital purchased a new stake in shares of Esperion Therapeutics during the third quarter worth about $173,000. Pacer Advisors Inc. purchased a new stake in shares of Esperion Therapeutics during the third quarter worth about $226,000. Keybank National Association OH grew its holdings in shares of Esperion Therapeutics by 97.7% during the second quarter. Keybank National Association OH now owns 7,663 shares of the biopharmaceutical company’s stock worth $300,000 after buying an additional 3,787 shares in the last quarter. Metropolitan Life Insurance Co. NY grew its holdings in shares of Esperion Therapeutics by 40.6% during the second quarter. Metropolitan Life Insurance Co. NY now owns 7,698 shares of the biopharmaceutical company’s stock worth $302,000 after buying an additional 2,224 shares in the last quarter. Finally, Canada Pension Plan Investment Board purchased a new stake in shares of Esperion Therapeutics during the second quarter worth about $333,000.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.

Featured Article: What is a Leveraged Buyout (LBO)?

Get a free copy of the Zacks research report on Esperion Therapeutics (ESPR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.